They manifest both combined immunodeficiency as well as metabolic abnormalities and are therefore commonly used to assess the effect of ADA deficiency not only on the lymphoid organs and peripheral blood, but also its systemic organ toxicity. The gene discussed is ADA; the disease is immunodeficiency disease.